Omidenepag Isopropyl

Omidenepag isopropyl
Clinical data
Trade names	Eybelis
Other names	DE-117
Identifiers
	IUPAC name Propan-2-yl 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate;
CAS Number	1187451-19-9;
PubChem CID	44230999;
DrugBank	DB15071;
UNII	G0G0H52U6K;
KEGG	D10966;
Chemical and physical data
Formula	C26H28N6O4S
Molar mass	520.61 g·mol−1

Omidenepag isopropyl (INN; trade name Eybelis) is a pharmaceutical drug used for the treatment of glaucoma and ocular hypertension.

Medical uses

Omidenepag isopropyl as a 0.002% ophthalmic solution was approved in Japan in 2018 for the treatment of glaucoma and ocular hypertension.^[1] It is being evaluated in the United States and Singapore for the same indications.^[1]

Adverse effects

The most common adverse effects of omidenepag isopropyl are conjunctival hyperemia and macular edema, including cystoid macular edema.^[1]

Pharmacology

Chemical structure of omidenepag, the active metabolite of omidenepag isopropyl

Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag.^[2] Omidenepag is a selective prostaglandin E2 receptor agonist.^[3]^[4]

History

Omidenepag isopropyl was developed by Ube Industries and Santen Pharmaceutical.^[1]

References

↑ ^1.0 ^1.1 ^1.2 ^1.3 "Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval". Drugs 78 (18): 1925–1929. December 2018. doi:10.1007/s40265-018-1016-1. PMID 30465134.
↑ "Omidenepag isopropyl". DrugCentral. Division of Translational Informatics at University of New Mexico. https://drugcentral.org/drugcard/5312.
↑ "Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent". Investigative Ophthalmology & Visual Science 59 (1): 145–153. January 2018. doi:10.1167/iovs.17-22745. PMID 29332128.
↑ "Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells". Scientific Reports 10 (1): 16018. September 2020. doi:10.1038/s41598-020-72538-x. PMID 32994409. Bibcode: 2020NatSR..1016018I.

0.00

(0 votes)

[Duggan-1] 1.0 ^1.1 ^1.2 ^1.3 "Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval". Drugs 78 (18): 1925–1929. December 2018. doi:10.1007/s40265-018-1016-1. PMID 30465134.

[2] "Omidenepag isopropyl". DrugCentral. Division of Translational Informatics at University of New Mexico. https://drugcentral.org/drugcard/5312.

[3] "Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent". Investigative Ophthalmology & Visual Science 59 (1): 145–153. January 2018. doi:10.1167/iovs.17-22745. PMID 29332128.

[4] "Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells". Scientific Reports 10 (1): 16018. September 2020. doi:10.1038/s41598-020-72538-x. PMID 32994409. Bibcode: 2020NatSR..1016018I.

[1]

[2]

[3]

[4]